Overview of hepatotoxicity of Xianling Gubao capsules

doi:10.19803/j.1672-8629.20230107

Abstract

Abstract: Objective To analyze the hepatotoxicity of Xianling Gubao capsules and provide reference for its safe and reasonable use. Methods By referring to the relevant literature at home and abroad from January 1994 to August 2022, the research situation of liver toxicity of Xianling Gubao capsules from the aspects of liver toxicity, cause of liver injury, toxicity mechanism and attenuated countermeasures was summarized. Results The toxic components of Xianling Gubao capsules are mainly Psoraleae Fructus and Epimedii Folium, which are related to factors such as patient’s gender, age and dosage. Conclusion The monitoring of hepatotoxicity of Xianling Gubao capsules should be strengthened in clinical use to reduce the occurrence of liver injury.

Key words: Xianling Gubao, capsules, hepatotoxicity, adverse drug reaction, liver injury, Psoraleae Fructus, Epimedii Folium

CLC Number:

R977
R994.11

ZHU Chunwu, YU Xuejun, SUN Xin, LIU Chenghai. Overview of hepatotoxicity of Xianling Gubao capsules[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 496-499.

References

[1] JIN FY, LIANG GY, ZHANG Z, et al.Studies on the quality standard for Xianling Gubao capsule[J]. Chin Pharm J(中国药学杂志), 2002, 37(5): 54-57.
[2] National Medical Products Administration. National Medical Products Administration has drawn attention to the drug risks of Xianling Gubao oral preparation[EB/OL]. (2016-12-08)[2023-03-26]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20161208170501622.html.
[3] Drug induced Liver Disease Study Group, Chinese society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol(临床肝胆病杂志), 2015, 31(11): 1752-1769.
[4] PENG SY, XIE YM, WANG ZF, et al.Analysis of adverse reactions of Xianling Gubao preparation based on real world SRS data[J]. China J Chin Mater Med(中国中药杂志), 2020, 45(10): 2316-2321.
[5] WANG ZF, PENG SY, XIE YM, et al.Real world multi-dimensional design of clinical safety research on Xianling Gubao preparation[J]. World Chin Med(世界中医药), 2020, 15(1): 7-12.
[6] YANG YH, ZHOU YL.Liver dysfunction resulting from Xianlinggubao capsules in 2 cases[J]. Adv Drug React J(药物不良反应杂志), 2007, 9(3): 214-215.
[7] LI S, WANG XJ, ZHUANG W, et al.Analysis of 39 cases of adverse reactions/events in Xianling Gubao capsules[J]. China Pharmacist(中国药师), 2019, 22(6): 1068-1071.
[8] GUO ZJ, LI P, KANG QJ, et al.Safety analysis and consideration on hepatotoxicity of Psoralea corylifolia L.[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2022, 37(5): 2616-2621.
[9] QIN ZF, YAO ZH, DAI Y, et al.HPLC-MS/MS analysis of the absorbed components in serum after intragastric administration of Xianlinggubao to rats[J]. J Instrumental Anal(分析测试学报), 2013, 32(4): 420-426.
[10] LIN HW, JIANG HX, LU WS, et al.Study on hepatotoxicity of Xianling Gubao extract and its unilateral extracts[J]. Pharm Care Res(药学服务与研究), 2020, 20(2): 98-101.
[11] HUANG Y, LIU YL, MA RY, et al.Clinical case analysis and disassembled prescription study of liver injury related to Xianling Gubao[J]. Acta Pharm Sin(药学学报), 2021, 56(1): 266-273.
[12] GUO ZJ, ZHANG JX, KANG QJ, et al.Comparative study on hepatotoxicity of Psoraleae Fructus in rats and mice[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2020, 26(22): 16-25.
[13] YANG C, YAO C.Clinical analysis and treatment of 10 cases of liver injury caused by Xianlinggubao capsule[J]. Anti Infect Pharm(抗感染药学), 2021, 18(9): 1366-1369.
[14] WANG Y, ZHANG H, JIANG JM, et al.Hepatotoxicity induced by psoralen and isopsoralen from Fructus Psoraleae: Wistar rats are more vulnerable than ICR mice[J]. Food Chem Toxicol, 2019, 125: 133-140.
[15] ZHANG Y, BI YN, YUAN XM, et al.Study on hepatotoxic components of Psoraleae Fructus based on target organs[J]. Lishizhen Med Mater Med Res(时珍国医国药), 2017, 28(8): 1844-1847.
[16] HUANG JY, WANG Q, BI YN, et al.Effect of isopsoralen on hepatic function and bile acid transporters in SD rats with different administration periods[J]. Chin Pharmacol Bull(中国药理学通报), 2019, 35(2): 260-264.
[17] ZHONG YH, SHEN GL, YUAN M, et al.Evaluation of cytochrome P450 inhibition and induction by psoralen and isopsoralen in vitro[J]. Chin J Pharmacol Toxicol(中国药理学与毒理学杂志), 2012, 26(4): 522-528.
[18] ZHOU K, WANG AH, CHAI LJ, et al.Cytotoxicity of bakuchiol on HepG2 cells and effects of BSEP, NTCP, FXR, CYP7A1[J]. J Toxicol(毒理学杂志), 2015, 29(3): 193-196.
[19] HU XJ, ZHANG YB, ZHAO ZJ, et al.Metabolic detoxification of bakuchiol is mediated by oxidation of CYP 450s in liver microsomes[J]. Food Chem Toxicol, 2018, 111: 385-392.
[20] GUO ZJ.Study on drug factors, toxicity mechanism and material basis of Psoraleae Fructus hepatotoxicity[D]. Beijing: Beijing University of Traditional Chinese Medicine, 2021.
[21] GUO ZJ, LI P, WANG CG, et al.Five constituents contributed to the Psoraleae Fructus-induced hepatotoxicity via mitochondrial dysfunction and apoptosis[J]. Front Pharmacol, 2021, 12: 682823.
[22] ZHOU K, BI YN, SHI H.Psoralen induced bile acid accumulation and cytotoxicity by inhibiting MRP2 and MRP3 in HepG2 cells[J]. Chin Pharmacol Bull(中国药理学通报), 2015, 31(8): 1112-1116.
[23] ZHANG XJ, CAO HQ, XING ZH, et al.Effects of Psoralea corylifolia L. on hepatocyte morphology, liver function and mitochondrial membrane potential in mice[J]. Chin Tradit Patent Med(中成药), 2014, 36(1): 160-162.
[24] ZHANG Y, LI J, CHEN Y, et al.The role of hepatic antioxidant capacity and hepatobiliary transporter in liver injury induced by isopsoralen in zebrafish larvae[J]. Hum Exp Toxicol, 2018, 1(9): 1-9.
[25] WANG D, JIA DX, LI ZZ, et al.Discussion on safety evaluation and risk control measures of Epimedii Folium[J]. China J Chin Mater Med(中国中药杂志), 2019, 44(8): 1715.
[26] ZHANG L, ZHANG JX, FAN QY, et al.Hepatoxicity of epimedii folium in rat model based on uniform design and regression analysis[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2018, 24(6): 189-197.
[27] WANG ZL.Susceptible components and mechanism studies of Epimedii Folium-induced immunological idiosyncratic liver injury based on NLRP3 inflammasome[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2021.
[28] GAO Y, WANG ZL, TANG JF, et al.New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14: 68-80.
[29] CHENG JH, CAI HD.Adverse reactions to Zhuangguguanjie Wan and cause analysis[J]. Adv Drug React J(药物不良反应杂志), 2000, 1(1): 15-19.
[30] ZHU CW, WANG HN, ZHANG YL, et al.Liver injury caused by Xianlinggubao capsules[J]. Chin Hepatol(肝脏), 2018, 23(12): 1090-1093.
[31] YANG K.Sex difference characteristics and serum metabonomics study of liver injury in rats caused by psoralen and isopsoralen[D]. Nanchang: Jiangxi University of Traditional Chinese Medicine, 2021.
[32] ZHAO XW, XU CL.Hepatic injury and hepatitis B virus reactivation due to concomitant use of Xianlinggubao capsules and omeprazole[J]. Adv Drug React J(药物不良反应杂志), 2012, 14(1): 60-61.
[33] ZHENG MJ, ZHOU Y, LYU XQ.Xianlinggubao capsules combined with diclofenac sodium sustained-release capsules to cause liver failure: a case report[J]. Chinese Journel of Pharmacovigilance(中国药物警戒), 2014, 11(8): 507-508.
[34] GUO ZJ, ZHANG JX, TU C, et al.Thoughts on several issues of potential hepatotoxicity in Chinese medicines[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2020, 35(11): 5399-5402.
[35] CAO SS, GONG S, YAN M, et al.Preventive effects of Danshen on cisplatin-induced hepatotoxicity[J]. Chin Pharmacol Bull(中国药理学通报), 2017, 33(1): 144-145.
[36] LU S, GUO JL, BIAO YN, et al.Effect of Danshen and Zexie on lipid metabolism and PPARα gene expression[J]. J Hebei Tradit Chin Med Pharmacol(河北中医药学报), 2022, 37(2): 45-48.
[37] ZHANG YF, CHEN L.The study of liver toxicity protective effects of tanshinone ⅡA to isoniazid and rifampicin in mice[J]. Henan J Prev Med(河南预防医学杂志), 2011, 22(5): 399-400.
[38] CHEN ZY, HUANG JS, XU YJ, et al.TanshinoneⅡa alleviates acute liver and kidney injury in septic rats[J]. Chin J Immunol(中国免疫学杂志), 2020, 36(13): 1578-1582.
[39] WANG WL, JYU DH, LIU MJ, et al.Research progress on pharmacology of effective components of dipsacales[J]. Chin J Med Guide(中国医药导刊), 2015, 17(10): 1059-1060.
[40] SONG D, CHEN SS, LI PY, et al.Attenuating the potential hepato-toxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method[J]. Acta Pharm Sin(药学学报), 2020, 55(2): 276-282.
[41] HONG L, WANG Z, TANG XH, et al.Processing of psoraleae fructus based on combination of Leigong method and salt processed method and its hepatotoxicity evaluation[J]. Chin Tradit Herb Drugs(中草药), 2021, 52(22): 6983-6989.